A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts.

Freya Biosciences is moving a microbial immunotherapy for IVF implantation failure into mid-stage trials after promising results in healthy volunteers. The Phase 2 study is

Abridge is partnering with top medical journals to bring in research for doctors to refer to during visits, pitting it against medical search giant OpenEvidence

The XBI is up 30% in six months, beating the S&P 500 by 24 percentage points — and the gap only widened in April.

In another signal of the deepening relationship between the pharma and AI sectors, Novartis CEO Vas Narasimhan has joined the board of Anthropic.